Selective Grp94 inhibitors and uses thereof

1. A compound of Formula (III):

or a pharmaceutically acceptable salt thereof, wherein:

(a) Y is —CH 2 — or —S—;

(b) each of Z 1 and Z 3 are independently —N—;

(c) Z 2 is —N— or —CH—;

(d) each of Z 6 , Z 7 and Z 8 are independently —C—;

(e) X 1 is —H or -halo;

(f) each of X 4 , X 5 , and X 6 are independently —H, -halo, or unsubstituted or substituted —(C 1 -C 6 )aliphatic;

(g) R 7 is —(C 1 -C 6 )aliphatic—N + (R 2 )(R 3 )(R 4 ), —(C 1 -C 6 )aliphatic —N—R 3 R 4 , —(C 1 -C 6 )aliphatic-alkenyl, or —(C 1 -C 6 )aliphatic-alkynyl, with the proviso that when all of R 2 -R 4 are present the compound further comprises a pharmaceutically acceptable counter ion;

(h) Q is fused benzo or fused (5- or 6-membered)heteroaryl;

(i) each of R 2 and R 3 are independently hydrogen or unsubstituted or substituted —(C 1 -C 6 )aliphatic;

(j) each R 4 is independently hydrogen, halogen, or unsubstituted or substituted —(C 1 -C 6 )aliphatic;

(k) each R 8 is independently —H, -halo, or an unsubstituted or substituted group selected from —CH 2 -phenyl or —(C 1 -C 6 )aliphatic;

(l) a is an integer selected from 0, 1 and 2; and

(m) each R is independently hydrogen or unsubstituted C 1-6 aliphatic;

wherein each substituted group is substituted with one or more groups selected from halo, —OR, —CN, or unsubstituted C 1-6 aliphatic.

2. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein:

(a) Y is —S—;

(b) each of Z 1 and Z 3 are independently —N—;

(c) Z 2 is —N—;

(d) each of Z 6 , Z 7 and Z 8 are independently —C—;

(e) X 1 is —H or -halo;

(f) each of X 4 , X 5 , and X 6 are independently —H, -halo, —(C 1 -C 6 )alkyl, —C(halo) 3 , —CH(halo) 2 , or —CH 2 (halo);

(g) R 7 is —(CH 2 ) m —N + (R 2 )(R 3 )(R 4 ), —(CH 2 ) m —N—R 3 R 4 , —(CH 2 ) m -alkenyl, or —(CH 2 ) m -alkynyl, where m is 1, 2, 3, 4 or 5, with the proviso that when all of R 2 -R 4 are present the compound further comprises a pharmaceutically acceptable counter ion;

(h) Q is selected from pyrrolo, pyridino, pyrimidino, pyrazino, pyridazino, oxadiazolo, thiadiazolo, and imidazolo;

(i) each of R 2 and R 3 are independently hydrogen, methyl, ethyl, ethenyl, ethynyl, propyl, butyl, pentyl, hexyl, isopropyl, t-butyl, isobutyl, —C(halo) 3 , —CH(halo) 2 , —CH 2 (halo), —CH 2 C(halo) 3 , —CHCH(halo) 2 , or CHCH 2 (halo);

(j) each R 4 is independently hydrogen, methyl, ethyl, isopropyl, t-butyl, isobutyl, or —C(halo) 3 ;

(k) each R 8 is independently —H, -halo, —(C 1 -C 6 )alkyl, —C(halo) 3 , —CH(halo) 2 , or —CH 2 (halo); and

(l) a is an integer selected from 0, 1 and 2.

3. The compound of claim 1 , having the following formula:

or a pharmaceutically acceptable salt thereof.

4. A pharmaceutical composition comprising a compound of claim 1 , and a pharmaceutically acceptable excipient.

5. A method of treating cancer, inflammatory diseases, rheumatoid arthritis, or diabetes in a patient, comprising administering a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein

the cancer is colorectal cancer, pancreatic cancer, thyroid cancer, basal cell carcinoma, melanoma, renal cell carcinoma, bladder cancer, prostate cancer, lung cancer, breast cancer, neuroblastoma, gastrointestinal cancer, liver cancer, gallbladder cancer, anal cancer, brain tumors, lymphomas, leukemias, myelomas, myeloproliferative neoplasms, gynecologic cancer, neck cancer, or Ewing's sarcoma; and

the inflammatory disease is lupus erythematosus, ischemia reperfusion injury, atherosclerotic lesions, antibiotic associated colitis, or septic shock.

6. A pharmaceutical composition comprising a compound of claim 3 , and a pharmaceutically acceptable excipient.

7. A method of treating cancer, inflammatory diseases, rheumatoid arthritis, or diabetes in a patient, comprising administering a therapeutically effective amount of a compound of claim 3 , or a pharmaceutically acceptable salt thereof, wherein

the cancer is colorectal cancer, pancreatic cancer, thyroid cancer, basal cell carcinoma, melanoma, renal cell carcinoma, bladder cancer, prostate cancer, lung cancer, breast cancer, neuroblastoma, gastrointestinal cancer, liver cancer, gallbladder cancer, anal cancer, brain tumors, lymphomas, leukemias, myelomas, myeloproliferative neoplasms, gynecologic cancer, neck cancer, or Ewing's sarcoma; and

the inflammatory disease is lupus erythematosus, ischemia reperfusion injury, atherosclerotic lesions, antibiotic associated colitis, or septic shock.

8. The compound of claim 1 , having the following formula:

wherein each R 9 is R, or a pharmaceutically acceptable salt thereof.

9. The compound of claim 1 , having the following formula:

or a pharmaceutically acceptable salt thereof.

10. The compound of claim 1 , having the following formula:

or a pharmaceutically acceptable salt thereof.

11. The compound of claim 1 , having the following formula:

or a pharmaceutically acceptable salt thereof.

12. A compound having the following formula:

or a pharmaceutically acceptable salt thereof.

13. A pharmaceutical composition comprising a compound of claim 12 , and a pharmaceutically acceptable excipient.

14. A method of treating cancer, inflammatory diseases, rheumatoid arthritis, or diabetes in a patient, comprising administering a therapeutically effective amount of a compound of claim 12 , or a pharmaceutically acceptable salt thereof, wherein

the cancer is colorectal cancer, pancreatic cancer, thyroid cancer, basal cell carcinoma, melanoma, renal cell carcinoma, bladder cancer, prostate cancer, lung cancer, breast cancer, neuroblastoma, gastrointestinal cancer, liver cancer, gallbladder cancer, anal cancer, brain tumors, lymphomas, leukemias, myelomas, myeloproliferative neoplasms, gynecologic cancer, neck cancer, or Ewing's sarcoma; and

the inflammatory disease is lupus erythematosus, ischemia reperfusion injury, atherosclerotic lesions, antibiotic associated colitis, or septic shock.

15. A pharmaceutical composition comprising a compound of claim 9 , and a pharmaceutically acceptable excipient.

16. A method of treating cancer, inflammatory diseases, rheumatoid arthritis, or diabetes in a patient, comprising administering a therapeutically effective amount of a compound of claim 9 , or a pharmaceutically acceptable salt thereof, wherein

the cancer is colorectal cancer, pancreatic cancer, thyroid cancer, basal cell carcinoma, melanoma, renal cell carcinoma, bladder cancer, prostate cancer, lung cancer, breast cancer, neuroblastoma, gastrointestinal cancer, liver cancer, gallbladder cancer, anal cancer, brain tumors, lymphomas, leukemias, myelomas, myeloproliferative neoplasms, gynecologic cancer, neck cancer, or Ewing's sarcoma; and

the inflammatory disease is lupus erythematosus, ischemia reperfusion injury, atherosclerotic lesions, antibiotic associated colitis, or septic shock.

17. A pharmaceutical composition comprising a compound of claim 10 , and a pharmaceutically acceptable excipient.

18. A method of treating cancer, inflammatory diseases, rheumatoid arthritis, or diabetes in a patient, comprising administering a therapeutically effective amount of a compound of claim 10 , or a pharmaceutically acceptable salt thereof, wherein

the cancer is colorectal cancer, pancreatic cancer, thyroid cancer, basal cell carcinoma, melanoma, renal cell carcinoma, bladder cancer, prostate cancer, lung cancer, breast cancer, neuroblastoma, gastrointestinal cancer, liver cancer, gallbladder cancer, anal cancer, brain tumors, lymphomas, leukemias, myelomas, myeloproliferative neoplasms, gynecologic cancer, neck cancer, or Ewing's sarcoma; and

the inflammatory disease is lupus erythematosus, ischemia reperfusion injury, atherosclerotic lesions, antibiotic associated colitis, or septic shock.

19. A pharmaceutical composition comprising a compound of claim 11 , and a pharmaceutically acceptable excipient.

20. A method of treating cancer, inflammatory diseases, rheumatoid arthritis, or diabetes in a patient, comprising administering a therapeutically effective amount of a compound of claim 11 , or a pharmaceutically acceptable salt thereof, wherein

the cancer is colorectal cancer, pancreatic cancer, thyroid cancer, basal cell carcinoma, melanoma, renal cell carcinoma, bladder cancer, prostate cancer, lung cancer, breast cancer, neuroblastoma, gastrointestinal cancer, liver cancer, gallbladder cancer, anal cancer, brain tumors, lymphomas, leukemias, myelomas, myeloproliferative neoplasms, gynecologic cancer, neck cancer, or Ewing's sarcoma; and

the inflammatory disease is lupus erythematosus, ischemia reperfusion injury, atherosclerotic lesions, antibiotic associated colitis, or septic shock.

21. A method of treating cancer in a patient comprising administering a therapeutically effective amount of a compound of any one of claims 1 , 3 , and 9 - 12 , or a pharmaceutically acceptable salt thereof, wherein the cancer is small cell lung cancer, non-small cell lung cancer, a gastrointestinal stromal tumor, gastric cancer, esophageal cancer, stomach cancer, glioma, follicular lymphoma, diffuse large B-cell lymphoma, ovarian cancer, cervical cancer, or endometrial cancer.